XML 104 R47.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Disclosures about major customers and credit risk | 12 Months Ended
--- | ---
Dec. 31, 2024
Disclosure of disaggregation of revenue from contracts with customers [abstract] |
Disclosure of revenue [text block] | D.34. Revenue from contracts with customers D.34.1. Analysis of net sales The table below sets forth Sanofi’s net sales for the years ended December 31, 2024, 2023 and 2022:
(€ million) | Europe | United States | Other countries | 2024 | Europe | United States | Other countries | 2023(a) | Europe | United States | Other countries | 2022(a)
Total Group | 9,027 | 19,986 | 12,068 | 41,081 | 8,816 | 17,262 | 11,739 | 37,817 | 8,490 | 16,986 | 12,175 | 37,651
Immunology |  |  |  |  |  |  |  |  |  |  |  |
of which | Dupixent | 1,618 | 9,544 | 1,910 | 13,072 | 1,224 | 8,145 | 1,346 | 10,715 | 940 | 6,346 | 1,006 | 8,292
Rare diseases |  |  |  |  |  |  |  |  |  |  |  |
of which | ALTUVIIIO | — | 617 | 65 | 682 | — | 155 | 4 | 159 | — | — | — | —
| Nexviazyme | 201 | 361 | 105 | 667 | 100 | 272 | 53 | 425 | 17 | 158 | 21 | 196
| Cablivi | 93 | 136 | 20 | 249 | 98 | 112 | 17 | 227 | 94 | 110 | 7 | 211
| Xenpozyme | 46 | 81 | 24 | 151 | 31 | 52 | 8 | 91 | 15 | 5 | 1 | 21
| Enjaymo | 17 | 58 | 30 | 105 | 6 | 42 | 24 | 72 | — | 17 | 5 | 22
Neurology |  |  |  |  |  |  |  |  |  |  |  |
of which | Aubagio | 152 | 187 | 40 | 379 | 437 | 460 | 58 | 955 | 511 | 1,420 | 98 | 2,029
Oncology |  |  |  |  |  |  |  |  |  |  |  |
of which | Sarclisa | 134 | 200 | 137 | 471 | 111 | 165 | 105 | 381 | 88 | 127 | 79 | 294
Other medicines |  |  |  |  |  |  |  |  |  |  |  |
of which | Rezurock | 28 | 425 | 17 | 470 | 5 | 303 | 2 | 310 | 1 | 206 | — | 207
| Tzield | 1 | 52 | 1 | 54 | — | 25 | — | 25 | — | — | — | —
Industrial sales | 520 | 1 | 2 | 523 | 528 | 4 | 19 | 551 | 580 | 17 | 11 | 608
Vaccines |  |  |  |  |  |  |  |  |  |  |  |
of which | Influenza Vaccines | 640 | 1,433 | 482 | 2,555 | 694 | 1,406 | 569 | 2,669 | 681 | 1,737 | 559 | 2,977
| Polio/Pertussis/ Hib Vaccines | 497 | 679 | 1,565 | 2,741 | 477 | 721 | 1,568 | 2,766 | 479 | 787 | 1,594 | 2,860
| RSV vaccines (Beyfortus) | 440 | 1,068 | 178 | 1,686 | 140 | 407 | — | 547 | — | — | — | —
| Meningitis, travel and endemics vaccines | 204 | 736 | 376 | 1,316 | 157 | 730 | 379 | 1,266 | 112 | 767 | 430 | 1,309
Of which total launches | 960 | 2,998 | 577 | 4,535 | 491 | 1,533 | 213 | 2,237 | 215 | 623 | 113 | 951
(a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. D.34.2. Other revenues
(€ million) | 2024 | 2023(a) | 2022(a)
VaxServe sales of non-Sanofi products | 1,959 | 2,167 | 1,567
COVID-19 vaccine related revenues | — | 509 | 257
Intragroup sales from continuing to discontinued operations (b) | 163 | 188 | 208
Royalties | 121 | 107 | 103
Other(c) | 623 | 534 | 399
Total Biopharma Other revenues | 2,866 | 3,505 | 2,534
Sales / Revenues from Opella products(d) | 339 | 296 | 376
Total Other revenues | 3,205 | 3,801 | 2,910
(a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation. (b)Revenues generated by legal entities within the scope of continuing operations from the manufacture of Opella products on behalf of legal entities within the scope of discontinued operations. (c)This line mainly includes revenues received under agreements for Sanofi to provide manufacturing services to third parties. (d)Consumer Healthcare activities that will not be transferred on the effective date of loss of control of Opella. These are primarily (i) hospital sales of Opella products in China, the transfer of which will be finalized no earlier than 2028 after a transitional period required to complete the transfer plan agreed with Sanofi in the context of public tendering arrangements ; (ii) sales made by the dedicated entity Opella Russie, the equity interests in which will be retained by Sanofi. Sanofi will continue to distribute Opella products in Russian territory under the distribution agreement signed in connection with the separation, the parties reserving the right to discuss the transfer of this retained interest during the distribution agreement term ; and (iii) sales of the Gold Bond product range, which are continuing in the United States through the retained subsidiary Gold Bond LLC (holder of the associated worldwide property rights).
Disclosure of disaggregation of revenue from contracts with customers [text block] | The table below sets forth Sanofi’s net sales for the years ended December 31, 2024, 2023 and 2022:
(€ million) | Europe | United States | Other countries | 2024 | Europe | United States | Other countries | 2023(a) | Europe | United States | Other countries | 2022(a)
Total Group | 9,027 | 19,986 | 12,068 | 41,081 | 8,816 | 17,262 | 11,739 | 37,817 | 8,490 | 16,986 | 12,175 | 37,651
Immunology |  |  |  |  |  |  |  |  |  |  |  |
of which | Dupixent | 1,618 | 9,544 | 1,910 | 13,072 | 1,224 | 8,145 | 1,346 | 10,715 | 940 | 6,346 | 1,006 | 8,292
Rare diseases |  |  |  |  |  |  |  |  |  |  |  |
of which | ALTUVIIIO | — | 617 | 65 | 682 | — | 155 | 4 | 159 | — | — | — | —
| Nexviazyme | 201 | 361 | 105 | 667 | 100 | 272 | 53 | 425 | 17 | 158 | 21 | 196
| Cablivi | 93 | 136 | 20 | 249 | 98 | 112 | 17 | 227 | 94 | 110 | 7 | 211
| Xenpozyme | 46 | 81 | 24 | 151 | 31 | 52 | 8 | 91 | 15 | 5 | 1 | 21
| Enjaymo | 17 | 58 | 30 | 105 | 6 | 42 | 24 | 72 | — | 17 | 5 | 22
Neurology |  |  |  |  |  |  |  |  |  |  |  |
of which | Aubagio | 152 | 187 | 40 | 379 | 437 | 460 | 58 | 955 | 511 | 1,420 | 98 | 2,029
Oncology |  |  |  |  |  |  |  |  |  |  |  |
of which | Sarclisa | 134 | 200 | 137 | 471 | 111 | 165 | 105 | 381 | 88 | 127 | 79 | 294
Other medicines |  |  |  |  |  |  |  |  |  |  |  |
of which | Rezurock | 28 | 425 | 17 | 470 | 5 | 303 | 2 | 310 | 1 | 206 | — | 207
| Tzield | 1 | 52 | 1 | 54 | — | 25 | — | 25 | — | — | — | —
Industrial sales | 520 | 1 | 2 | 523 | 528 | 4 | 19 | 551 | 580 | 17 | 11 | 608
Vaccines |  |  |  |  |  |  |  |  |  |  |  |
of which | Influenza Vaccines | 640 | 1,433 | 482 | 2,555 | 694 | 1,406 | 569 | 2,669 | 681 | 1,737 | 559 | 2,977
| Polio/Pertussis/ Hib Vaccines | 497 | 679 | 1,565 | 2,741 | 477 | 721 | 1,568 | 2,766 | 479 | 787 | 1,594 | 2,860
| RSV vaccines (Beyfortus) | 440 | 1,068 | 178 | 1,686 | 140 | 407 | — | 547 | — | — | — | —
| Meningitis, travel and endemics vaccines | 204 | 736 | 376 | 1,316 | 157 | 730 | 379 | 1,266 | 112 | 767 | 430 | 1,309
Of which total launches | 960 | 2,998 | 577 | 4,535 | 491 | 1,533 | 213 | 2,237 | 215 | 623 | 113 | 951
(a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 15 -IssueDate 2023-01-01 -Paragraph 114 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for revenue. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2023-01-01 -Paragraph 10 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfRevenueExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration